Welcome to our dedicated page for Oncolytics Biotech SEC filings (Ticker: ONCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oncolytics Biotech, Inc. (ONCY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent for pancreatic, breast, and gastrointestinal cancers. Its filings help investors understand how the company describes its programs, capital plans, and corporate structure.
Oncolytics files a range of documents, including Forms 6-K and 8-K that furnish or report material events and press releases. Recent 6-K reports have included information on the formation and expansion of a Gastrointestinal Tumor Scientific Advisory Board, progress toward pivotal and registration-directed studies in pancreatic, colorectal, and anal cancers, and details of an at-the-market sales agreement used to fund pelareorep’s clinical development and general corporate purposes. A Form 8-K has reported leadership appointments in strategy, operations, and biostatistics intended to support late-stage clinical execution.
Filings also describe corporate and jurisdictional changes, such as the proposed domestication from Alberta, Canada, to the State of Nevada in the United States, the company’s transition from foreign private issuer status to domestic issuer status, and related proxy and registration materials. These documents outline the rationale for reducing regulatory complexity, aligning domicile with U.S.-based operations and shareholders, and improving access to U.S. capital markets.
On Stock Titan, investors can review these SEC filings alongside AI-powered summaries that highlight key points, such as clinical trial plans, financing arrangements, and governance changes. Real-time updates from EDGAR, combined with AI explanations of complex documents like registration statements and current reports, help users quickly understand how ONCY’s regulatory disclosures relate to its immuno-oncology strategy and pelareorep development programs.
Oncolytics Biotech Inc. filed a Form 6-K as a foreign private issuer. The filing mainly updates how certain shareholder information is incorporated into an existing Canadian shelf-style registration statement on Form F-10. It states that Exhibit 99.1 to this Form 6-K, an information circular previously filed on July 8, 2025, is now incorporated by reference into Oncolytics Biotech Inc.’s Form F-10 registration statement (File No. 333-281009). The report is signed on behalf of the company by its Chief Financial Officer, Kirk Look.
FAQ
What is the current stock price of Oncolytics Biotech (ONCY)?
What is the market cap of Oncolytics Biotech (ONCY)?
